Show simple item record

dc.contributor.authorFöhr, Tiina
dc.contributor.authorHendrix, Arne
dc.contributor.authorKankaanpää, Anna
dc.contributor.authorLaakkonen, Eija K.
dc.contributor.authorKujala, Urho
dc.contributor.authorPietiläinen, Kirsi H.
dc.contributor.authorLehtimäki, Terho
dc.contributor.authorKähönen, Mika
dc.contributor.authorRaitakari, Olli
dc.contributor.authorWang, Xiaoling
dc.contributor.authorKaprio, Jaakko
dc.contributor.authorOllikainen, Miina
dc.contributor.authorSillanpää, Elina
dc.date.accessioned2024-02-01T12:38:00Z
dc.date.available2024-02-01T12:38:00Z
dc.date.issued2024
dc.identifier.citationFöhr, T., Hendrix, A., Kankaanpää, A., Laakkonen, E. K., Kujala, U., Pietiläinen, K. H., Lehtimäki, T., Kähönen, M., Raitakari, O., Wang, X., Kaprio, J., Ollikainen, M., & Sillanpää, E. (2024). Metabolic syndrome and epigenetic aging : a twin study. <i>International Journal of Obesity</i>, <i>Early online</i>. <a href="https://doi.org/10.1038/s41366-024-01466-x" target="_blank">https://doi.org/10.1038/s41366-024-01466-x</a>
dc.identifier.otherCONVID_202788093
dc.identifier.urihttps://jyx.jyu.fi/handle/123456789/93208
dc.description.abstractBackground Metabolic syndrome (MetS) is associated with premature aging, but whether this association is driven by genetic or lifestyle factors remains unclear. Methods Two independent discovery cohorts, consisting of twins and unrelated individuals, were examined (N = 268, aged 23–69 years). The findings were replicated in two cohorts from the same base population. One consisted of unrelated individuals (N = 1 564), and the other of twins (N = 293). Participants’ epigenetic age, estimated using blood DNA methylation data, was determined using the epigenetic clocks GrimAge and DunedinPACE. The individual-level linear regression models for investigating the associations of MetS and its components with epigenetic aging were followed by within-twin-pair analyses using fixed-effects regression models to account for genetic factors. Results In individual-level analyses, GrimAge age acceleration was higher among participants with MetS (N = 56) compared to participants without MetS (N = 212) (mean 2.078 [95% CI = 0.996,3.160] years vs. −0.549 [−1.053,−0.045] years, between-group p = 3.5E-5). Likewise, the DunedinPACE estimate was higher among the participants with MetS compared to the participants without MetS (1.032 [1.002,1.063] years/calendar year vs. 0.911 [0.896,0.927] years/calendar year, p = 4.8E-11). An adverse profile in terms of specific MetS components was associated with accelerated aging. However, adjustments for lifestyle attenuated these associations; nevertheless, for DunedinPACE, they remained statistically significant. The within-twin-pair analyses suggested that genetics explains these associations fully for GrimAge and partly for DunedinPACE. The replication analyses provided additional evidence that the association between MetS components and accelerated aging is independent of the lifestyle factors considered in this study, however, suggesting that genetics is a significant confounder in this association. Conclusions The results of this study suggests that MetS is associated with accelerated epigenetic aging, independent of physical activity, smoking or alcohol consumption, and that the association may be explained by genetics.en
dc.format.mimetypeapplication/pdf
dc.language.isoeng
dc.publisherNature Publishing Group
dc.relation.ispartofseriesInternational Journal of Obesity
dc.rightsCC BY 4.0
dc.subject.otherepigeneettinen ikääntyminen
dc.subject.othergenetics
dc.subject.othersigns and symptoms
dc.subject.otherepigenetic aging
dc.titleMetabolic syndrome and epigenetic aging : a twin study
dc.typeresearch article
dc.identifier.urnURN:NBN:fi:jyu-202402011716
dc.contributor.laitosLiikuntatieteellinen tiedekuntafi
dc.contributor.laitosFaculty of Sport and Health Sciencesen
dc.contributor.oppiaineGerontologia ja kansanterveysfi
dc.contributor.oppiaineLiikuntalääketiedefi
dc.contributor.oppiaineHyvinvoinnin tutkimuksen yhteisöfi
dc.contributor.oppiaineFyysinen aktiivisuus eliniän aikanafi
dc.contributor.oppiaineGerontology and Public Healthen
dc.contributor.oppiaineSports and Exercise Medicineen
dc.contributor.oppiaineSchool of Wellbeingen
dc.contributor.oppiainePhysical activity through life spanen
dc.type.urihttp://purl.org/eprint/type/JournalArticle
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1
dc.description.reviewstatuspeerReviewed
dc.relation.issn0307-0565
dc.relation.volumeEarly online
dc.type.versionpublishedVersion
dc.rights.copyright© 2024 the Authors
dc.rights.accesslevelopenAccessfi
dc.type.publicationarticle
dc.relation.grantnumber346509
dc.relation.grantnumber275323
dc.relation.grantnumber330281
dc.relation.grantnumber326242
dc.relation.grantnumber341750
dc.subject.ysoikä
dc.subject.ysokaksostutkimus
dc.subject.ysoelintavat
dc.subject.ysoperimä
dc.subject.ysovanheneminen
dc.subject.ysoaineenvaihdunta
dc.subject.ysometabolinen oireyhtymä
dc.subject.ysoepigenetiikka
dc.subject.ysoympäristötekijät
dc.format.contentfulltext
jyx.subject.urihttp://www.yso.fi/onto/yso/p1229
jyx.subject.urihttp://www.yso.fi/onto/yso/p18525
jyx.subject.urihttp://www.yso.fi/onto/yso/p5530
jyx.subject.urihttp://www.yso.fi/onto/yso/p8862
jyx.subject.urihttp://www.yso.fi/onto/yso/p470
jyx.subject.urihttp://www.yso.fi/onto/yso/p3066
jyx.subject.urihttp://www.yso.fi/onto/yso/p6238
jyx.subject.urihttp://www.yso.fi/onto/yso/p24631
jyx.subject.urihttp://www.yso.fi/onto/yso/p6194
dc.rights.urlhttps://creativecommons.org/licenses/by/4.0/
dc.relation.doi10.1038/s41366-024-01466-x
dc.relation.funderSuomen Akatemiafi
dc.relation.funderSuomen Akatemiafi
dc.relation.funderSuomen Akatemiafi
dc.relation.funderSuomen Akatemiafi
dc.relation.funderSuomen Akatemiafi
dc.relation.funderResearch Council of Finlanden
dc.relation.funderResearch Council of Finlanden
dc.relation.funderResearch Council of Finlanden
dc.relation.funderResearch Council of Finlanden
dc.relation.funderResearch Council of Finlanden
jyx.fundingprogramAkatemiatutkijan tutkimuskulut, SAfi
jyx.fundingprogramAkatemiahanke, SAfi
jyx.fundingprogramAkatemiahanke, SAfi
jyx.fundingprogramProfilointi, SAfi
jyx.fundingprogramAkatemiatutkija, SAfi
jyx.fundingprogramResearch costs of Academy Research Fellow, AoFen
jyx.fundingprogramAcademy Project, AoFen
jyx.fundingprogramAcademy Project, AoFen
jyx.fundingprogramResearch profiles, AoFen
jyx.fundingprogramAcademy Research Fellow, AoFen
jyx.fundinginformationTF is supported by the Juho Vainio Foundation and the Yrjö Jahnsson Foundation. ES is supported by the Academy of Finland (grant numbers 341750, 346509, 260001), the Juho Vainio Foundation, the Päivikki and Sakari Sohlberg Foundation, and the Yrjö Jahnsson Foundation (6168). JK is supported by the Academy of Finland (grant numbers 213506, 308248, 312073, 336823), EC FP5 GenomEUtwin, NIH NIH/NHLBI (grant HL104125), EC MC ITN Project EPITRAIN, and the Sigrid Juselius Foundation. MO is supported by the Academy of Finland (grant numbers 328685, 307339, 297908 and 251316), EC MC ITN Project EPITRAIN, University of Helsinki Research Funds, and the Sigrid Juselius Foundation. KHP is supported by the Academy of Finland (grant numbers 272376, 266286, 314383, 335443), Finnish Medical Foundation, Finnish Diabetes Research Foundation, Novo Nordisk Foundation (NNF10OC1013354, NNF17OC0027232, NNF20OC0060547), Signe and Ane Gyllenberg Foundation, Sigrid Juselius Foundation, Government Research Funds for Helsinki University Hospital Research Funds, and the University of Helsinki. EKL was supported by the Academy of Finland (grant numbers 275323 and 330281) and the PACTS2 profiling action of the University of Jyväskylä funded by the Academy of Finland (326242). The Gerontology Research Center is a joint effort between the University of Jyväskylä and the University of Tampere. The YFS has been financially supported by the following sources: Academy of Finland (grant numbers 356405, 322098, 286284, 134309 (Eye), 126925, 121584, 124282, 255381, 256474, 283115, 319060, 320297, 314389, 338395, 330809, and 104821, 129378 (Salve), 117797 (Gendi), and 141071 (Skidi)); the Social Insurance Institution of Finland; Competitive State Research Financing of the Expert Responsibility Area of Kuopio, Tampere and Turku University Hospitals (grant X51001); the Juho Vainio Foundation; the Paavo Nurmi Foundation; the Finnish Foundation for Cardiovascular Research; the Finnish Cultural Foundation; the Sigrid Juselius Foundation; the Tampere Tuberculosis Foundation; the Emil Aaltonen Foundation; the Yrjö Jahnsson Foundation; the Signe and Ane Gyllenberg Foundation; the Diabetes Research Foundation of Finnish Diabetes Association; EU Horizon 2020 (grant 755320 for TAXINOMISIS and grant 848146 for To Aition); the European Research Council (grant 742927 for MULTIEPIGEN project); the Tampere University Hospital Supporting Foundation, Finnish Society of Clinical Chemistry; the Cancer Foundation Finland; pBETTER4U_EU (Preventing obesity through Biologically and bEhaviorally Tailored inTERventions for you; project number: 101080117); and the Jane and Aatos Erkko Foundation. The EH-Epi has been finally supported by the NIH/NHLBI grant HL104125. Open Access funding provided by University of Jyväskylä (JYU).
dc.type.okmA1


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

CC BY 4.0
Except where otherwise noted, this item's license is described as CC BY 4.0